rs2298566 — SNX19

SNX19 — The Endolysosomal Positioning Factor Linked to Coronary Risk

Deep inside every cell, a network of membrane-bound organelles sorts, degrades, and recycles proteins and lipids¹¹ sorts, degrades, and recycles proteins and lipids
Endolysosomes are the cell's recycling centers; their positioning determines how efficiently cargo is processed. SNX19 — Sorting Nexin 19 — is a molecular tether that anchors endolysosomes to the endoplasmic reticulum (ER), keeping them clustered near the cell nucleus rather than scattered throughout the cytoplasm. A common missense variant in SNX19, rs2298566, alters one of the protein's functional domains and has been associated with elevated coronary heart disease risk in prospective cohort data.

The Mechanism

SNX19 bridges two organelle systems: its two N-terminal transmembrane domains embed the protein in the ER membrane, while its PX domain²² PX domain
Phox Homology domain — a phosphoinositide-binding module found across the sorting nexin family binds phosphatidylinositol 3-phosphate (PI3P) on endolysosomal membranes. Regulatory PXA and PXC flanking domains act as a molecular governor, preventing excessive tethering under normal conditions. The variant rs2298566 is a missense change that substitutes leucine at position 878 with arginine (p.Leu878Arg) in the major isoform — a significant amino acid property change within the regulatory C-terminal region.

When endolysosomal positioning is disrupted — as demonstrated by Saric et al., Nature Communications 2021³³ Saric et al., Nature Communications 2021
NIH National Institute of Child Health and Human Development using SNX19-knockout cells — endolysosomes disperse throughout the cytoplasm and exhibit increased motility. Perinuclear clustering of endolysosomes is important for efficient lysosomal degradation of oxidized LDL, inflammatory signaling complexes, and autophagy substrates. Disruption of this compartment organization is implicated in the accumulation of intracellular lipid and inflammatory cargo relevant to vascular cell biology.

The precise molecular bridge between altered SNX19 tethering and coronary artery disease risk is not yet established at the mechanistic level. SNX19's role in endolysosomal positioning is consistent with the broader evidence that lysosomal dysfunction contributes to macrophage foam cell formation, cholesterol efflux impairment, and vascular inflammation — central processes in atherosclerosis.

The Evidence

The primary evidence for rs2298566's cardiovascular association comes from the Atherosclerosis Risk in Communities (ARIC) study. Bare et al., Genetics in Medicine 2007⁴⁴ Bare et al., Genetics in Medicine 2007
Cohort study with Cox proportional hazards modeling, 9,129 white participants, median 13-year follow-up assembled five variants — rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8) — each of which had prior CHD associations. Among participants with a high composite genetic risk score (the top 4% of carriers), the hazard ratio for incident CHD was 1.57 (95% CI 1.21–2.04; p = 0.001) after adjustment for traditional cardiovascular risk factors; bootstrap validation suggested HR 1.43 in external populations. The paper states rs2298566 had been "confirmed in two studies" prior to ARIC inclusion.

It is important to note the limitations. The published effect size is for the composite five-SNP score — individual effect sizes for rs2298566 alone are not reported in the abstract, and its specific contribution to the composite has not been disaggregated in the literature retrieved. The KIF6 variant (rs20455), which was the most prominent member of this panel, later failed to replicate across large independent cohorts. Whether rs2298566 independently replicates at genome-wide significance has not been established in a GWAS meta-analysis. The evidence level is accordingly rated moderate rather than strong.

Practical Actions

For A-allele carriers, the most actionable steps target the lipid-processing and inflammatory pathways that SNX19's endolysosomal role touches. Monitoring the early biomarkers of cardiovascular risk — lipids and vascular inflammation — allows timely intervention at the stage before clinical coronary disease develops.

There are no specific drug-gene interactions or nutrient interventions documented for rs2298566 in the current literature. Statin response differential has been proposed for genes in this five-SNP panel but has not been established for SNX19 specifically.

Interactions

rs2298566 was studied as one of five CHD-associated variants alongside rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), and rs1010 (VAMP8). The composite risk score framework suggests additive rather than synergistic effects across these loci, as each gene operates through largely distinct mechanisms (cytoskeletal dynamics, actin scaffolding, vesicle trafficking). The cardiovascular relevance of SNX19 may also intersect with the 11q25 psychiatric risk locus; SNX19 transcript diversity at this locus is regulated by chromatin accessibility changes relevant to the same cis-regulatory region.